This post was originally published on this site
(Reuters) – The Federal Trade Commission said on Tuesday it will launch an inquiry into the prescription drug middleman industry, sending compulsory orders to six pharmacy benefit managers for records on their business practices.
As part of the inquiry, the antitrust body will send orders to CVS Health Corp (NYSE:CVS)’s Caremark, Humana Inc (NYSE:HUM), Cigna Corp (NYSE:CI)’s Express Scripts (NASDAQ:ESRX) and UnitedHealth Group (NYSE:UNH)’s OptumRx, among others.
